Research Analysts Set Expectations for TRVI FY2025 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Trevi Therapeutics in a report released on Tuesday, July 1st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($0.39) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Cantor Fitzgerald also issued estimates for Trevi Therapeutics’ FY2026 earnings at ($0.47) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.04.

TRVI has been the subject of a number of other reports. Wall Street Zen lowered shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, June 6th. D. Boral Capital restated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Monday, June 2nd. B. Riley reaffirmed a “buy” rating and issued a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. HC Wainwright started coverage on Trevi Therapeutics in a research report on Wednesday, May 28th. They set a “buy” rating and a $21.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 price target on shares of Trevi Therapeutics in a research report on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.88.

Trevi Therapeutics Stock Down 1.4%

Shares of TRVI stock opened at $5.90 on Thursday. Trevi Therapeutics has a 12-month low of $2.36 and a 12-month high of $7.48. The firm has a fifty day moving average of $6.29 and a 200-day moving average of $5.38. The company has a market capitalization of $691.54 million, a price-to-earnings ratio of -13.10 and a beta of 0.46.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Summit Investment Advisors Inc. lifted its position in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after purchasing an additional 2,894 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Trevi Therapeutics in the 4th quarter valued at approximately $49,000. Strs Ohio bought a new stake in shares of Trevi Therapeutics during the 1st quarter worth approximately $52,000. Squarepoint Ops LLC acquired a new stake in shares of Trevi Therapeutics during the 4th quarter worth approximately $58,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of Trevi Therapeutics during the 4th quarter worth approximately $66,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.